Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
CERo Therapeutics Holdings ( (CERO) ) has provided an announcement.
On June 11, 2025, CERo Therapeutics Holdings received a notification from Nasdaq regarding its common stock’s failure to meet the minimum bid price requirement of $1.00 per share over a 30-day period. In response, the company conducted a reverse stock split on June 13, 2025, at a ratio of 1 for 20, which temporarily raised the stock price above the required threshold. However, the company remains uncertain about maintaining compliance and securing its Nasdaq listing, pending a hearing with the Nasdaq Hearings Panel.
The most recent analyst rating on (CERO) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on CERo Therapeutics Holdings stock, see the CERO Stock Forecast page.
More about CERo Therapeutics Holdings
CERo Therapeutics Holdings, Inc. operates in the biotechnology industry, focusing on developing innovative therapeutic solutions. The company is involved in creating treatments that target specific medical conditions, aiming to enhance patient outcomes and address unmet medical needs.
Average Trading Volume: 1,993,915
Technical Sentiment Signal: Sell
Current Market Cap: $2.85M
See more insights into CERO stock on TipRanks’ Stock Analysis page.